Blueprint Medicines (BPMC) Misses Q4 EPS by 12c, Miss on Revenues

Note: EPS may not be comparable

Blueprint Medicines (NASDAQ: BPMC) reported Q4 EPS of ($1.23), $0.12 worse than the analyst estimate of ($1.11). Revenue for the quarter came in at $1.63 million versus the consensus estimate of $5.28 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Wintermar acquires full control of Fast Offshore Supply, adding 5 new CTVs
• Robinhood prices $2B convertible notes offering due 2029